Edition:
United States

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

90.27EUR
6:42am EST
Change (% chg)

€-0.29 (-0.32%)
Prev Close
€90.56
Open
€90.12
Day's High
€90.81
Day's Low
€89.80
Volume
183,620
Avg. Vol
565,364
52-wk High
€115.20
52-wk Low
€89.04

Latest Key Developments (Source: Significant Developments)

Orexigen Therapeutics announces commercialization and distributorship agreement with Merck KGaA, Darmstadt
Monday, 13 Nov 2017 08:08am EST 

Nov 13 (Reuters) - Orexigen Therapeutics Inc :Orexigen Therapeutics announces commercialization and distributorship agreement with Merck KGaA, Darmstadt, Germany for contrave in Latin America.Orexigen Therapeutics - ‍Orexigen will receive an upfront payment and other potential regulatory and sales milestones, which have not been disclosed​.Orexigen Therapeutics Inc - ‍merck KGaA, Darmstadt, Germany will be responsible for all commercialization and regulatory activities ​.Orexigen Therapeutics Inc - ‍Orexigen will also be responsible for product supply​.Orexigen Therapeutics Inc - ‍under terms of agreement, Merck KGaA, Darmstadt, Germany will own marketing authorization in region​.  Full Article

BRIEF-Merck KGaA, Samsung Biologics sign MoU on strategic alliance
Wednesday, 1 Nov 2017 02:11am EDT 

Corrects company name in headline:Says MilliporeSigma signs memorandum of understanding (MoU) with Samsung Biologics for strategic alliance on biopharma manufacturing, biologics process development‍​.The new MoU is an extension of one signed in 2014 that encompasses a long-term supply agreement.  Full Article

GSK will look at Pfizer, Merck consumer assets if offered for sale
Wednesday, 25 Oct 2017 07:47am EDT 

Oct 25 (Reuters) - GlaxoSmithKline CEO Emma Walmsley tells reporters::as world leader in consumer healthcare, we will look at Pfizer consumer health.bulking up consumer is one option but top priority is boosting pharma pipeline.moving forward with Brexit contingency planning, would like to know about transition asap.needs clarity on Brexit implementation phase of at least 2 years.not thinking of any relocation out of UK as a result of brexit.would also look carefully at German Merck consumer assets.new pharma head Miels very focused on launch of 3 critical new products.happy to continue to work with Novartis on consumer health or take over stake if Novartis wants to sell.  Full Article

Merck KGaA: Canadian patent office to grant patent application for CRISPR technology
Tuesday, 24 Oct 2017 08:12am EDT 

Oct 24 (Reuters) - MERCK KGAA ::MERCK KGAA - CANADIAN PATENT OFFICE TO GRANT MERCK KGAA, DARMSTADT, GERMANY'S PATENT APPLICATION FOR CRISPR TECHNOLOGY.FIRST PATENT ALLOWANCE FOR COMPANY’S CRISPR TECHNOLOGY IN NORTH AMERICA‍​.  Full Article

Merck KGaA says 2017 guidance range achievable, but challenging
Thursday, 28 Sep 2017 05:10am EDT 

Sept 28 (Reuters) - Merck Kgaa managers on call::CFO says we still believe we will make our 2017 guidance range, but it is very challenging.CEO says no plans for a fourth pillar, any acquisitions will remain within framework of three pillars.  Full Article

Merck KGAA appoints Paolo Carli head of Middle East, Africa & Turkey for healthcare business‍​
Monday, 25 Sep 2017 07:50am EDT 

Sept 25 (Reuters) - Merck KGAA :Merck KGAA - announced appointment of Paolo Carli as head of Middle East, Africa & Turkey (MEA) region for its healthcare business‍​.  Full Article

Merck KGaA's Bavencio drug wins EU approval for Merkel cell carcinoma
Thursday, 21 Sep 2017 03:11am EDT 

Sept 21 (Reuters) - Merck KGaA ::European commission approves Bavencio (avelumab) for metastatic Merkel cell carcinoma.  Full Article

Merck KGaA to enter into strategic collaboration with Project Data Sphere LLC
Monday, 11 Sep 2017 05:22am EDT 

Sept 11 (Reuters) - MERCK KGAA ::WILL ENTER INTO A STRATEGIC COLLABORATION WITH PROJECT DATA SPHERE LLC.  Full Article

Merck to acquire Natrix Separations
Monday, 28 Aug 2017 08:00am EDT 

Aug 28 (Reuters) - Merck KGaA ::Merck to acquire Natrix Separations to advance next-generation processing capabilities.Merck says the transaction is expected to close in Q3 of 2017; financial details were not disclosed.  Full Article

Merck KGaA to decide over next few mths over U.S. filing of cladribine
Thursday, 3 Aug 2017 04:30am EDT 

Aug 3 (Reuters) - Merck KGaA :CEO says liquid crystal market share now at slightly above 60 percent, to decline to 50-60 percent over next 2 yrs.CEO says to report over next few months whether to seek U.S. Approval for MS drug Mavenclad/cladribine.  Full Article

BRIEF-Orexigen Therapeutics announces commercialization and distributorship agreement with Merck KGaA, Darmstadt

* Orexigen Therapeutics announces commercialization and distributorship agreement with Merck KGaA, Darmstadt, Germany for contrave in Latin America